These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31593801)

  • 21. A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia.
    Enjeti AK; D'Crus A; Melville K; Verrills NM; Rowlings P
    Anticancer Drugs; 2016 Jul; 27(6):560-8. PubMed ID: 26967515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
    Cristóbal I; Garcia-Orti L; Cirauqui C; Cortes-Lavaud X; García-Sánchez MA; Calasanz MJ; Odero MD
    Haematologica; 2012 Apr; 97(4):543-50. PubMed ID: 22133779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia.
    Toop HD; Dun MD; Ross BK; Flanagan HM; Verrills NM; Morris JC
    Org Biomol Chem; 2016 May; 14(20):4605-16. PubMed ID: 27102578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction.
    De Palma RM; Parnham SR; Li Y; Oaks JJ; Peterson YK; Szulc ZM; Roth BM; Xing Y; Ogretmen B
    FASEB J; 2019 Jun; 33(6):7647-7666. PubMed ID: 30917007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.
    Zonta F; Pagano MA; Trentin L; Tibaldi E; Frezzato F; Trimarco V; Facco M; Zagotto G; Pavan V; Ribaudo G; Bordin L; Semenzato G; Brunati AM
    Blood; 2015 Jun; 125(24):3747-55. PubMed ID: 25931585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia.
    Arriazu E; Pippa R; Odero MD
    Front Oncol; 2016; 6():78. PubMed ID: 27092295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.
    Velmurugan BK; Lee CH; Chiang SL; Hua CH; Chen MC; Lin SH; Yeh KT; Ko YC
    J Cell Physiol; 2018 Feb; 233(2):1300-1311. PubMed ID: 28516459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia.
    Ma W; Xiang Y; Yang R; Zhang T; Xu J; Wu Y; Liu X; Xiang K; Zhao H; Liu Y; Si Y
    J Pharmacol Sci; 2019 Apr; 139(4):304-310. PubMed ID: 30852180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FTY720 induces non-canonical phosphatidylserine externalization and cell death in acute myeloid leukemia.
    Young MM; Bui V; Chen C; Wang HG
    Cell Death Dis; 2019 Nov; 10(11):847. PubMed ID: 31699964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer.
    Cristóbal I; Rincón R; Manso R; Caramés C; Zazo S; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Clin Cancer Res; 2015 Jan; 21(2):347-56. PubMed ID: 25388166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.
    Cristóbal I; González-Alonso P; Daoud L; Solano E; Torrejón B; Manso R; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mar Drugs; 2015 May; 13(6):3276-86. PubMed ID: 26023836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells.
    Wallington-Beddoe CT; Hewson J; Bradstock KF; Bendall LJ
    Autophagy; 2011 Jul; 7(7):707-15. PubMed ID: 21460633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of Novel FTY720 Analogs with Anticancer Activity through PP2A Activation.
    Shrestha J; Ki SH; Shin SM; Kim SW; Lee JY; Jun HS; Lee T; Kim S; Baek DJ; Park EY
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30355990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FTY720 Inhibits Expansion of Breast Cancer Stem Cells via PP2A Activation.
    Hirata N; Yamada S; Yanagida S; Ono A; Kanda Y
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review.
    Cristóbal I; Madoz-Gúrpide J; Manso R; González-Alonso P; Rojo F; García-Foncillas J
    Curr Med Res Opin; 2016 Jun; 32(6):1137-41. PubMed ID: 26950691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma.
    Kubota D; Yoshida A; Kawai A; Kondo T
    J Proteome Res; 2014 May; 13(5):2250-61. PubMed ID: 24621013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Penfluridol triggers cytoprotective autophagy and cellular apoptosis through ROS induction and activation of the PP2A-modulated MAPK pathway in acute myeloid leukemia with different FLT3 statuses.
    Wu SY; Wen YC; Ku CC; Yang YC; Chow JM; Yang SF; Lee WJ; Chien MH
    J Biomed Sci; 2019 Aug; 26(1):63. PubMed ID: 31470848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
    McCracken AN; McMonigle RJ; Tessier J; Fransson R; Perryman MS; Chen B; Keebaugh A; Selwan E; Barr SA; Kim SM; Roy SG; Liu G; Fallegger D; Sernissi L; Brandt C; Moitessier N; Snider AJ; Clare S; Müschen M; Huwiler A; Kleinman MT; Hanessian S; Edinger AL
    Leukemia; 2017 Mar; 31(3):669-677. PubMed ID: 27573555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FTY720 induces ferroptosis and autophagy via PP2A/AMPK pathway in multiple myeloma cells.
    Zhong Y; Tian F; Ma H; Wang H; Yang W; Liu Z; Liao A
    Life Sci; 2020 Nov; 260():118077. PubMed ID: 32810509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.